Navigation Links
Anthrax inhibitors identified by Burnham team

A collaborative team of scientists led by The Burnham Institute's Maurizio Pellecchia, Ph.D., has identified inhibitors of the anthrax toxin, termed lethal factor ("LF") that could be developed into an emergency treatment for exposure to inhalation anthrax. These findings will be published by the Proceedings of the National Academy of Sciences by Early Edition at the journal's website the week of June 20th.

Bacillus anthracis ("anthrax") is a proven agent of biological terrorism. Pulmonary anthrax, in which spores of the anthrax bacteria are inhaled, is typically fatal unless diagnosis is made at an early stage of infection, when antibiotics such as Ciprofloxacin can provide a complete cure. At late stages in the disease, antibiotics can kill the anthrax bacteria, but do not affect LF secreted by the bacteria, which is sufficiently concentrated in the bloodstream. LF enters cells and inactivates a human protein called "mitogen-activated protein kinase", or "MAPKK", disrupting the normal signaling pathways of the cell and inducing cell-death.

Using a fragment-based approach based on assays conducted with highly sensitive nuclear magnetic resonance ("NMR") techniques developed in Dr. Pellecchia's laboratory, the scientists were able to identify a scaffold that served as a template for designing a preferred structure for small-molecule inhibitors of LF. Lead compounds were synthesized and validated as highly potent and selective against LF in vitro. In in vitro assays, the compounds did not affect prototype human metalloproteinase enzymes that are structurally similar to LF. This is very important as selectivity is a fundamental prerequisite for a drug to be safe for use in humans.

Three lead compounds where tested in mice infected with anthrax spores, in combination with the antibiotic Ciprofloxacin. The survival rate for mice treated with each of the compounds tested in the combination therapy was two-fold over mice treated with Ciprofloxacin a
'"/>

Source:Burnham Institute


Page: 1 2 3

Related biology news :

1. Study Models Impact Of Anthrax Vaccine
2. Anthrax test, developed by army and CDC, receives FDA approval
3. Anthrax stops body from fighting back, study shows
4. Anthrax spores may survive water treatment
5. Anthrax inhibitor counteracts toxin, may lead to new therapeutics
6. Anthrax attack posed greater potential threat than thought
7. Anthrax paralyzes immune cells with lethal toxin, UF research shows
8. Protease inhibitors reach beyond HIV
9. Enzyme inhibitors block replication of SARS virus
10. Sweet water taste paradoxically predicts sweet taste inhibitors
11. COX-2 inhibitors significantly reduce risk of cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anthrax inhibitors identified Burnham team

(Date:4/15/2014)... (KNAW) has announced the names of five internationally renowned ... million US dollars prize money in total). The laureates ... science. , This year marks the 50th anniversary of ... Erwin Chargaff in 1964. , KNAW juries have ... , Christopher M. Dobson, John Humphrey Plummer ...
(Date:4/15/2014)... 2050, deforestation could cause temperatures in the Congo ... would intensify warming caused by greenhouse gases by ... the University of Leuven, Belgium. , Explosive population ... destruction of tropical rainforests in Central Africa. A ... examined how these practices will affect longer-term temperatures ...
(Date:4/15/2014)... cuttlefish, squid and octopus has uncovered details of ... they may help in investigating populations of their ... 10 new parasite species− dicyemid mesozoans −, which ... and octopus). They are the very first ... , "Although dicyemid parasites have been studied ...
Breaking Biology News(10 mins):Five scientists awarded prestigious Heineken Prizes 2Study: Deforestation could intensify climate change in Congo Basin by half 2Bizarre parasite may provide cuttlefish clues 2
... This press release is available in Spanish . ... radiotherapy to the lymph nodes located behind the breast bone ... breast conserving surgery, a radiation oncologist will tell delegates at ... March). Women at a high risk of developing breast cancer ...
... may shed light on how climate over millions of years ... that will discuss the findings and recommendations of the National ... Several members of the committee that wrote the report will ... next 10 to 20 years and answer audience questions. ...
... (LF) and the Nanyang Technological University (NTU) today announced ... to poor communities in the region with fresh funds, ... programme. The Lien Foundation is injecting a ... (Endeavour). Started in 2006, the Endeavour seeks to improve ...
Cached Biology News:Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients 2NTU and Lien Foundation launch second second wave of Environmental Endeavor 2NTU and Lien Foundation launch second second wave of Environmental Endeavor 3
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... (OTCBB: GNLK, "the Company," or "GeneLink"), a leading consumer ... year ended December 31, 2010. Financial Highlights: ... 2009 to $4,997,367 in 2010; Annual net sales ... 2009; Operating losses in 2010 decreased to $2,169,898, a ...
... SEATTLE, April 4, 2011 Omeros Corporation (NASDAQ: ... developing and commercializing products focused on inflammation, bleeding and ... Gregory A. Demopulos, M.D., chairman and chief executive officer, ... Healthcare Conference taking place in New York City this ...
... proteins, polymers, minerals, and engineered materials will be published ... Nature Materials . The discovery by two Penn State ... the structure of materials, which the researchers say greatly ... desired properties. The research is expected to have broad ...
Cached Biology Technology:GeneLink Reports 2010 Results 2Search for advanced materials aided by discovery of hidden symmetries in nature 2Search for advanced materials aided by discovery of hidden symmetries in nature 3
... Combining linear motor and ballscrew ... pre-engineered Cartesian solutions that include ... management, and motors., , ... Pass through high-flex cabling for ...
UGT1A6 (D-20)...
... T Squareds patented high efficiency dynamic valve ... With the most compact, lightweight package in ... use in portable air and gas applications., ... high efficiency. , Includes DC Motor. ...
... designed for moving loads quickly and accurately. ... output while limiting overall size. The P5S-P ... ball bearings guided on two rails., ... provide energy absorption and controlled deceleration , ...
Biology Products: